{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:56:04Z","timestamp":1784717764186,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["IRG-116731"],"award-info":[{"award-number":["IRG-116731"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.canlet.2025.217775","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:25:15Z","timestamp":1746530715000},"page":"217775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy"],"prefix":"10.1016","volume":"626","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-1782","authenticated-orcid":false,"given":"Shuying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gagea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-6711","authenticated-orcid":false,"given":"Lorenzo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-7131","authenticated-orcid":false,"given":"Kim-Anh","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0144-9614","authenticated-orcid":false,"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gonzalez-Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.canlet.2025.217775_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.canlet.2025.217775_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.canlet.2025.217775_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12951-020-00758-4","article-title":"Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib4","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217775_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"19","key":"10.1016\/j.canlet.2025.217775_bib6","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217775_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.canlet.2025.217775_bib8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217775_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2025.217775_bib10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"IMpassion130 trial investigators. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217775_bib11","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","volume":"8","author":"Collignon","year":"2016","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2025.217775_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.canlet.2025.217775_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217775_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217775_bib16","first-page":"5155","article-title":"Chemoresistance in breast cancer: PI3K\/Akt pathway inhibitors vs the current chemotherapy","volume":"11","author":"Kaboli","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217775_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.146171","article-title":"Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K\/Akt signaling under cytotoxic stress","volume":"816","author":"Jabbarzadeh Kaboli","year":"2022","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.canlet.2025.217775_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/dbio.1995.1152","article-title":"ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain","volume":"169","author":"Wolfsberg","year":"1995","journal-title":"Dev. Biol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","article-title":"The ADAM metalloproteinases","volume":"29","author":"Edwards","year":"2008","journal-title":"Mol. Aspect. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.217775_bib20","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/0008-5472.CAN-03-3235","article-title":"Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis","volume":"64","author":"Shintani","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.jnen.0000229240.51490.d3","article-title":"Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness","volume":"65","author":"Wildeboer","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217775_bib22","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1158\/1078-0432.CCR-06-2092","article-title":"ADAM-17 expression in breast cancer correlates with variables of tumor progression","volume":"13","author":"McGowan","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/sj.bjc.6601645","article-title":"ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma","volume":"90","author":"Gr\u00fctzmann","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.canlet.2025.217775_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0303-7207(00)00305-1","article-title":"The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone","volume":"167","author":"McCulloch","year":"2000","journal-title":"Mol. Cell. Endocrinol."},{"issue":"24","key":"10.1016\/j.canlet.2025.217775_bib25","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1158\/1078-0432.CCR-06-1066","article-title":"Molecular profiling of ADAM12 in human bladder cancer","volume":"12","author":"Fr\u00f6hlich","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00428-004-1193-z","article-title":"Expression of ADAM15 in lung carcinomas","volume":"446","author":"Sch\u00fctz","year":"2005","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/emboj\/cdg111","article-title":"TACE is required for the activation of the EGFR by TGF-alpha in tumors","volume":"22","author":"Borrell-Pag\u00e8s","year":"2003","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.canlet.2025.217775_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ijc.11161","article-title":"Expression of ADAM-9 mRNA and protein in human breast cancer","volume":"105","author":"O'Shea","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"20","key":"10.1016\/j.canlet.2025.217775_bib29","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1158\/1078-0432.CCR-05-0560","article-title":"How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study","volume":"11","author":"Sieuwerts","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.217775_bib30","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-05-0262","article-title":"A role for ADAM12 in breast tumor progression and stromal cell apoptosis","volume":"65","author":"Kveiborg","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1593\/neo.05682","article-title":"ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease","volume":"8","author":"Kuefer","year":"2006","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.canlet.2025.217775_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI29518","article-title":"Targeting TACE-dependent EGFR ligand shedding in breast cancer","volume":"117","author":"Kenny","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"13 Suppl","key":"10.1016\/j.canlet.2025.217775_bib33","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1158\/1538-7445.AM2017-4736","article-title":"ADAMs, potential biomarkers and oncotargets in breast cancer","volume":"77","author":"Liu","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217775_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1749-6632.1999.tb07688.x","article-title":"Preclinical and clinical studies of MMP inhibitors in cancer","volume":"878","author":"Drummond","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2025.217775_bib35","first-page":"513","article-title":"Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions","volume":"5","author":"Macaulay","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217775_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13058-023-01665-w","article-title":"Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment","volume":"25","author":"Liu","year":"2023","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2025.217775_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/1535-7163.MCT-18-0710","article-title":"Cooperative effect of oncogenic MET and PIK3CA in an HGF-dominant environment in breast cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/annonc\/mds530","article-title":"Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy","volume":"24","author":"Gonzalez-Angulo","year":"2013","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217775_bib39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ccr.2009.03.027","article-title":"Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases","volume":"15","author":"Liu","year":"2009","journal-title":"Cancer Cell"},{"issue":"7418","key":"10.1016\/j.canlet.2025.217775_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib41","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.18632\/oncotarget.3094","article-title":"Functional consequence of the MET-T1010I polymorphism in breast cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.canlet.2025.217775_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157612","article-title":"Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression","volume":"7","author":"Najem","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600957","article-title":"A murine preclinical syngeneic transplantation model for breast cancer precision medicine","volume":"3","author":"Federico","year":"2017","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm1764","article-title":"Stromal gene expression predicts clinical outcome in breast cancer","volume":"14","author":"Finak","year":"2008","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1608","article-title":"Gene expression signatures of morphologically normal breast tissue identify basal-like tumors","volume":"8","author":"Finak","year":"2006","journal-title":"Breast Cancer Res."},{"issue":"Pt 1","key":"10.1016\/j.canlet.2025.217775_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/bj3270037","article-title":"Angiotensin-converting enzyme secretase is inhibited by zinc metalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer","volume":"327","author":"Parvathy","year":"1997","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/toxins8040122","article-title":"A disintegrin and metalloprotease (ADAM): historical overview of their functions","volume":"8","author":"Giebeler","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib48","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood-2002-12-3775","article-title":"The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion","volume":"102","author":"Hundhausen","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib49","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138620710791054259","article-title":"Fluorescent substrates useful as high-throughput screening tools for ADAM9","volume":"13","author":"Moss","year":"2010","journal-title":"Comb. Chem. High Throughput Screen."},{"issue":"3","key":"10.1016\/j.canlet.2025.217775_bib50","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.181.3.1205","article-title":"A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes","volume":"181","author":"Crowe","year":"1995","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217775_bib51","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.4049\/jimmunol.155.11.5198","article-title":"A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor","volume":"155","author":"M\u00fcllberg","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2025.217775_bib52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fimmu.2020.00499","article-title":"Targeting ADAM10 in cancer and autoimmunity","volume":"11","author":"Smith","year":"2020","journal-title":"Front. Immunol."},{"issue":"1 Pt A","key":"10.1016\/j.canlet.2025.217775_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.imlet.2014.08.008","article-title":"ADAM17 at the interface between inflammation and autoimmunity","volume":"162","author":"Lisi","year":"2014","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.canlet.2025.217775_bib54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/intimm\/2.6.585","article-title":"Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage","volume":"2","author":"Yoshida","year":"1990","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217775_bib55","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mds279","article-title":"ADAM-17: a novel therapeutic target for triple negative breast cancer","volume":"24","author":"McGowan","year":"2013","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2025.217775_bib56","doi-asserted-by":"crossref","first-page":"19543","DOI":"10.1074\/jbc.M410943200","article-title":"Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)\/ADAM-17","volume":"280","author":"Fabre-Lafay","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.canlet.2025.217775_bib57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5966\/sctm.2015-0168","article-title":"A disintegrin and metalloproteinase domain 17 regulates colorectal cancer stem cells and chemosensitivity via Notch1 signaling","volume":"5","author":"Wang","year":"2016","journal-title":"Stem Cells Transl. Med."},{"issue":"6","key":"10.1016\/j.canlet.2025.217775_bib58","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/bjc.2014.55","article-title":"Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity","volume":"110","author":"Gooden","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"42","key":"10.1016\/j.canlet.2025.217775_bib59","doi-asserted-by":"crossref","first-page":"30114","DOI":"10.1074\/jbc.M113.459255","article-title":"Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells","volume":"288","author":"Woods","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.canlet.2025.217775_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107738","article-title":"Rapid and efficient invasion assay of glioblastoma in human brain organoids","volume":"31","author":"Goranci-Buzhala","year":"2020","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.canlet.2025.217775_bib61","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.3390\/cancers13102459","article-title":"CX3CL1 overexpression prevents the formation of lung metastases in trastuzumab-treated MDA-MB-453-based humanized tumor mice (HTM)","volume":"13","author":"Wege","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.canlet.2025.217775_bib62","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrc2459","article-title":"The ADAMs: signalling scissors in the tumour microenvironment","volume":"8","author":"Murphy","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217775_bib63","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.onc.1207278","article-title":"Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion","volume":"23","author":"Sch\u00e4fer","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2025.217775_bib64","first-page":"383","article-title":"mTOR function and therapeutic targeting in breast cancer","volume":"7","author":"Hare","year":"2017","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.217775_bib65","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bcp.12958","article-title":"The therapeutic potential of mTOR inhibitors in breast cancer","volume":"82","author":"Steelman","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217775_bib66","first-page":"3333","article-title":"Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Qiao","year":"2014","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:51:05Z","timestamp":1778471465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525003416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":66,"alternative-id":["S0304383525003416"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217775","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217775"}}